力生制药
(002393)
| 流通市值：40.56亿 | | | 总市值：41.65亿 |
| 流通股本：3.00亿 | | | 总股本：3.08亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 641,633,361.63 | 332,282,846.72 | 1,392,014,298.29 | 1,007,280,440.26 |
| 营业收入 | 641,633,361.63 | 332,282,846.72 | 1,392,014,298.29 | 1,007,280,440.26 |
| 二、营业总成本 | 545,482,254.7 | 275,933,687.7 | 1,237,397,826.21 | 871,042,976.72 |
| 营业成本 | 284,307,265.35 | 148,480,217.84 | 622,787,319.63 | 424,869,882.93 |
| 税金及附加 | 10,739,390 | 5,442,807.77 | 23,741,412.15 | 16,807,326.2 |
| 销售费用 | 155,104,926.43 | 77,812,332.46 | 374,553,639.51 | 280,142,605.86 |
| 管理费用 | 64,081,760.17 | 30,559,500.45 | 149,763,102.5 | 105,314,299.64 |
| 研发费用 | 40,371,747.75 | 19,977,674.28 | 115,192,280.36 | 90,304,744.13 |
| 财务费用 | -9,122,835 | -6,338,845.1 | -48,639,927.94 | -46,395,882.04 |
| 其中:利息费用 | 817,041.36 | 456,052.01 | 2,253,830.01 | 1,911,285.95 |
| 其中:利息收入 | 10,200,002.27 | 6,801,948.25 | 51,522,258.82 | 49,091,990.84 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,033,638.05 | 1,353,392.89 | 2,105,592.51 | 2,398,652.06 |
| 加:投资收益 | 9,522,841.21 | 3,306,226.21 | 324,770,617.56 | 319,543,582.3 |
| 资产处置收益 | - | - | 249,613.79 | 282,628.85 |
| 资产减值损失(新) | -15,188,814.65 | - | -20,080,500.19 | -16,435,037.58 |
| 信用减值损失(新) | -153,088.55 | 7,251.56 | 868,226.05 | 294,758.51 |
| 其他收益 | 3,534,622.2 | 1,361,839.04 | 6,600,782.15 | 3,679,718.55 |
| 四、营业利润 | 94,900,305.19 | 62,377,868.72 | 469,130,803.95 | 446,001,766.23 |
| 加:营业外收入 | 423,979.3 | 90,000.6 | 1,721,251.6 | 1,553,215.35 |
| 减:营业外支出 | 311,609.54 | 158,997.48 | 15,246,903.8 | 14,540,196.6 |
| 五、利润总额 | 95,012,674.95 | 62,308,871.84 | 455,605,151.75 | 433,014,784.98 |
| 减:所得税费用 | 14,936,755.23 | 9,243,309.67 | 32,878,707.12 | 58,729,889.06 |
| 六、净利润 | 80,075,919.72 | 53,065,562.17 | 422,726,444.63 | 374,284,895.92 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 80,075,919.72 | 53,065,562.17 | 422,726,444.63 | 374,284,895.92 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 78,326,032.27 | 51,882,970.53 | 416,283,339.38 | 370,740,371.53 |
| 少数股东损益 | 1,749,887.45 | 1,182,591.64 | 6,443,105.25 | 3,544,524.39 |
| 扣除非经常损益后的净利润 | 67,042,045.29 | 46,869,507.4 | 168,529,342.94 | 126,730,212.35 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.25 | 0.2 | 1.62 | 1.44 |
| (二)稀释每股收益 | 0.25 | 0.2 | 1.62 | 1.44 |
| 八、其他综合收益 | 769,832.25 | 2,438,356.16 | -412,435,477.98 | - |
| 归属于母公司股东的其他综合收益 | 769,832.25 | 2,438,356.16 | -412,435,477.98 | - |
| 九、综合收益总额 | 80,845,751.97 | 55,503,918.33 | 10,290,966.65 | 374,284,895.92 |
| 归属于母公司股东的综合收益总额 | 79,095,864.52 | 54,321,326.69 | 3,847,861.4 | 374,284,895.92 |
| 归属于少数股东的综合收益总额 | 1,749,887.45 | 1,182,591.64 | 6,443,105.25 | - |
| 公告日期 | 2026-08-21 | 2026-04-24 | 2026-03-25 | 2025-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |